Glenmark Pharma rating – Buy: Sustained rise in cash flows key to rerating

Estimates tweaked to factor in listing of API subsidiary; ‘Buy’ maintained with an unchanged TP of Rs 757

from The Financial Express https://ift.tt/38uhH4h
https://ift.tt/eA8V8J Nomura